Almirall Q3 EPS misses as sales climb 10%
Investing.com · · AI-summarised by FinFlash
Spanish drugmaker Almirall reported third-quarter adjusted earnings per share of $0.08, below the $0.13 expected, with revenue of $290.5 million versus a $295.35 million forecast. Q3 net sales still grew 10.1% to 286.5 million euros, and nine-month sales rose 8.3% to 889 million euros, led by Ebglyss, up 75%. The company kept 2026 guidance of 9% to 12% sales growth and 270 to 290 million euros of EBITDA. Shares fell 2.3%.
So What?
The miss weighs on the stock near term, but early achievement of its 2028 margin target supports the biologics thesis; watch Germany's January 2027 rebate reform, flagged as a 1% to 2.5% revenue headwind.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.